How to Identify a False Positive Syphilis Test

A reactive result on an initial syphilis screening test does not, by itself, establish that a patient has syphilis. That reality catches both patients and clinicians off guard more often than it should. Several conditions can produce antibodies that react with syphilis assays, including pregnancy, autoimmune disease and some infections. That is why a reactive screening result needs to be interpreted in context and, in most serologic testing pathways, alongside a complementary test.

A false positive syphilis test is a recognised feature of syphilis serology rather than an unusual laboratory failure. Understanding why it happens, which test patterns are most likely to mislead and what current CDC recommendations mean for discordant results is essential for accurate reporting and patient care.

Why Syphilis Testing Produces False Positives

Syphilis diagnosis should not rest on a single serologic test result. The reason is structural: the two main categories of serologic tests detect different antibody responses and are designed to be interpreted together.

Non-treponemal tests such as RPR (Rapid Plasma Reagin) and VDRL (Venereal Disease Research Laboratory) detect antibodies that react with lipoidal antigens used in the assay, typically a cardiolipin-lecithin-cholesterol complex. These antibodies can appear during syphilis, but they can also be produced in other clinical settings. That is why a reactive RPR or VDRL can represent a biological false positive rather than active Treponema pallidum infection.

Treponemal tests such as FTA-ABS, TPHA, TPPA and CLIA detect antibodies directed against T. pallidum antigens. They are more specific than non-treponemal tests but can still produce false-positive results. Treponemal antibodies also remain reactive long term in most previously infected patients, even after successful treatment, although seroreversion can occur in some people treated very early.

For serologic diagnosis, treponemal and non-treponemal results are generally interpreted together. Direct detection methods can also provide confirmatory evidence in appropriate clinical settings.

What Causes a False Positive Syphilis Test

The list is longer than most people expect. A false positive syphilis test is most likely with non-treponemal tests, but treponemal tests are not safe from it either.

Cause	How It Affects Testing
Pregnancy	Can be associated with biological false-positive non-treponemal reactions
Systemic lupus erythematosus	Anticardiolipin and antiphospholipid antibodies cross-react with RPR and VDRL antigens
Antiphospholipid syndrome	Directly produces anticardiolipin antibodies, mimicking syphilis serology
HIV infection	May be associated with biological false-positive non-treponemal reactions
Hepatitis B or C	Can be associated with non-specific non-treponemal reactivity
Malaria	Can trigger non-specific antibody responses
Recent vaccinations	Temporary immune activation can contribute to biological false-positive reactions
Intravenous drug use	Biological false positive RPR reactions
Other treponemal infections (yaws, pinta)	Direct cross-reactivity with treponemal antigens
Chronic liver disease	Can be associated with non-specific antibody reactivity
Advanced age	Background biological false-positive reactions are more common with older age

A large retrospective study involving 35,995 syphilis tests was published online in October 2025 and subsequently appeared in its 2026 journal issue. It found that biological false-positive reactions were associated with several clinical factors, including autoimmune disease and autoantibodies. Autoimmune conditions such as systemic lupus erythematosus and antiphospholipid antibody positivity are especially relevant because anticardiolipin and related antibodies can react with the lipoidal antigens used in RPR and VDRL assays.

A false positive syphilis test does not, by itself, diagnose antiphospholipid syndrome. StatPearls notes that antiphospholipid syndrome requires specific clinical and laboratory criteria. If a biological false-positive reaction persists or occurs alongside clinical features suggestive of autoimmune disease, further evaluation may be appropriate.

Also check for Hepatitis B Surface Antigen Test

Biological False Positive RPR and VDRL: How Common Are They

Biological false-positive non-treponemal reactions vary by population and testing setting. One Indian study reported biological false positives in about 11% of VDRL-reactive samples, which is not the same as 11% of everyone tested. In pregnancy studies using reverse-sequence treponemal EIA or CIA screening, high false-positive proportions have also been reported among initially reactive screens when the RPR is negative. Those figures apply to specific low-prevalence pregnancy cohorts and should not be generalised to all treponemal tests or all populations. USPSTF evidence likewise shows why follow-up testing is essential after a reactive screen.

A reactive treponemal screen with a non-reactive RPR cannot be labelled a false positive from those two results alone. It can reflect previous treated infection, very early infection or a false-positive treponemal result. CDC laboratory recommendations advise adjudicating this discordant pattern with a second treponemal test that uses a different format or antigen target, with TP-PA preferred as a manual treponemal test.

What the 2026 CDC Surveillance Case Definitions Mean for Labs

CDC's 2026 syphilis case definitions are surveillance definitions. They are designed to standardise how public-health agencies classify and count cases, not to replace clinical diagnostic guidance or determine patient management.

That distinction matters because surveillance classification and clinical diagnosis serve different purposes. Clinical decisions should use current CDC testing recommendations, the patient's history, examination findings, treatment history and risk assessment. Surveillance definitions, meanwhile, specify the evidence required to classify reportable cases consistently across jurisdictions.

For laboratories, the practical lesson is to report syphilis serology completely and clearly. A reactive screening result should be accompanied by the complementary test and any recommended adjudication of discordant results whenever the testing algorithm calls for it. Complete documentation helps clinicians interpret results correctly and supports accurate public-health reporting, but the 2026 surveillance definitions do not create a universal rule that every case must contain both pieces of one serologic algorithm.

A January 2026 medRxiv preprint evaluated a research-use neonatal IgM assay in maternal-neonatal pairs at risk for congenital syphilis. The study suggested that treponemal IgM may have potential as a supplementary marker, but it did not establish CIA followed by RPR and TPPA as the definitive neonatal diagnostic pathway. Current CDC laboratory recommendations do not recommend an IgM test to diagnose congenital syphilis; neonatal evaluation instead relies on maternal history, examination and recommended serologic testing, including quantitative non-treponemal testing where indicated.

False Positive Syphilis Test in Pregnancy: The Stakes Are Higher Now

Pregnancy is a recognised setting in which biological false-positive non-treponemal results can occur. CDC laboratory recommendations estimate the rate at approximately 0.6% among pregnant persons, although the frequency varies by population and testing context.

Scale still matters. In a Pediatrics study of more than 75,000 pregnancies, 221 initial syphilis screens were positive. Of those, 183 were ultimately classified as false positives and 38 as true positives, producing an 83% false-discovery rate among the initially positive screens. That does not mean 83% of all pregnancy syphilis tests were false positive. It means that, in this study population, most initial positive screens did not represent true infection after the full diagnostic workup.

The consequences of getting the diagnosis wrong in either direction are serious. Untreated maternal syphilis can result in congenital syphilis and other adverse pregnancy outcomes. Unnecessary treatment can also cause avoidable medication exposure. In patients with true syphilis, treatment may trigger a Jarisch-Herxheimer reaction that can be associated with uterine contractions or fetal distress.

A single reactive screening result should not ordinarily be treated as definitive evidence of syphilis. In pregnancy, however, clinicians may need to make treatment decisions before the entire workup is complete when clinical suspicion is high or follow-up is uncertain. Current CDC guidance allows treatment to be considered in some isolated reactive treponemal-screen scenarios when reliable follow-up is unlikely.

Positive RPR, Negative Treponemal: Reading the Pattern

A reactive RPR with a non-reactive treponemal test is most consistent with a biological false-positive non-treponemal reaction rather than active syphilis. The pattern still needs to be interpreted in clinical context, especially when recent exposure or very early infection is possible.

The clinician should review symptoms, sexual history, treatment history and risk factors, and may repeat testing when early infection remains a concern. No diagnosis should be made from this pattern alone.

The reverse pattern, a reactive treponemal screen with a non-reactive RPR, is more complex. It can represent past successfully treated infection, very early active infection or a false-positive treponemal screen. CDC laboratory recommendations advise using a second treponemal assay with a different format or antigen target to adjudicate discordant results. TP-PA is the preferred manual treponemal test for this purpose.

Reverse-sequence screening can identify some infections that might otherwise be missed, but discordant results are more common in low-prevalence populations. A Medical News Today review also explains why false-positive results can occur. A reactive treponemal screen with a non-reactive RPR requires adjudication rather than an automatic diagnosis of either active syphilis or a false positive.

What Happens When You Receive a Reactive Screening Result

The first thing to establish is which test produced the result. Was it a non-treponemal screen or a treponemal screen? Has the other test type been run?

A single reactive screening result should not be presented to a patient as definitive proof of syphilis. The result should be explained as preliminary or incomplete until the complementary serologic test, relevant history and clinical findings have been considered. Clear communication matters because an isolated reactive result can cause substantial psychological and social harm.

For clinicians and laboratory staff, the testing sequence depends on whether the laboratory uses the traditional or reverse algorithm. In either approach, discordant serology should be resolved according to current CDC laboratory recommendations, including a second treponemal assay when indicated. The final report should document the results needed for interpretation rather than stopping at the first reactive screen.

How Flabs Supports Accurate Laboratory Reporting

Over 2,000 NABL-accredited labs across India run on Flabs LIS, a cloud-based laboratory information system built for pathology and diagnostic workflows. Managing syphilis serology well means capturing every step of the algorithm, not just the first reactive result.

• Structured serology report templates covering RPR, VDRL, TPHA, and treponemal confirmatory results
• Configurable reflex test workflows supporting both traditional and reverse testing algorithms
• AI-assisted report review supporting pathologist sign-off before result release
• Digital report delivery via WhatsApp, SMS, and email ensuring clinicians receive complete algorithmic results
• Audit-ready records for every result entered, reviewed, and authorised
• Role-based access ensuring only qualified staff release sensitive serology results
• The pathology reporting software at Flabs supports structured, algorithm-complete reporting so that a reactive first-step result reaches the clinician with the confirmatory context available in the workflow.

Try Flabs for a full month for just ₹1.

The Bottom Line

A false positive syphilis test is a recognised limitation of antibody-based testing, not necessarily a failure of the laboratory. Biological false-positive RPR and VDRL reactions, isolated reactive treponemal screens and discordant serology all have established interpretation pathways.

The 2026 CDC surveillance case definitions should be understood separately from clinical diagnostic guidance. For patient care, the key principle remains complete interpretation of the testing algorithm, appropriate adjudication of discordant results and clinical correlation before a reactive screen is treated as definitive evidence of infection.